Veterinary Blog
Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates
Featuring
Veterinary Targeted Therapies in the Time of COVID-19, Part 1
Dr. London is a global leader in veterinary targeted therapies. She discusses potential risks to veterinary staff, the value of targeted therapy in times of constrained PPE resources, and the effects of COVID-19 on research activity.
Webinars
Featuring
Unique Perspective: Cancer Biologist & Pet Cancer Parent
When your dog has cancer and you're also a world-renowned cancer researcher, your interactions with veterinary oncologists are a little different.
Introducing Olaparib to the FidoCure® Veterinary Oncology Toolbox
Another exciting addition to the FidoCure® oncology toolbox: Olaparib as a new targeted therapy.
Safety and Toxicity of Small Molecule Inhibitors in Dogs with Spontaneously Occurring Malignancies — The Use of Real World Data
The VCS Virtual Conference was held from October 15 - 17, 2020. We had the honor of presenting our abstract during the event.
Introducing Palbociclib: A New Targeted Therapy
We are thrilled to announce a new targeted therapy, Palbociclib, as part of the FidoCure® oncology toolbox.
ProductFeaturing
Great Danes to Grandads: Comparative Cancer and Aging Research
Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine.
WebinarsHSA Genomic Data: FidoCure® and Mason
On August 13, 2020, FidoCure® hosted a webinar with Dr. Nicola Mason, B.Vet.Med, PhD, DACVIM (Internal Medicine).
DataTargeted Therapy Efficacious Dose Finding: The Case for Agile Design
Why is the Palladia dose used at the clinic often different from the one on the FDA-approved label? Over 100 human targeted therapies have been approved, yet many doses were found to be incorrect in the post market stage. Why is that?
DataFeaturing
Personalized Medicine: Because Not All Tumors Are Created Equally
Dr. Mason shares insight from the groundbreaking work her team is doing with hemangiosarcoma genetics and discussses the findings from her research on immunology and its influence on the future of veterinary medicine.
WebinarsReal World Evidence - Uses and Opportunities
This follow-up dives deeper into the ways that RWE is being used in human oncology and where there are parallel opportunities in the veterinary space.
Foundational ReadsLiterature Support for Targeted Therapy
In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.
Foundational Reads
